Diane M. Simeone, MD

Diane M. Simeone, MD, discusses the phase 1/2 EVEREST-1 trial evaluating the autologous CAR T-cell therapy A2B530 in patients with solid tumors.

Diane M. Simeone, MD, discusses the importance of germline testing in pancreatic cancer.

Diane M. Simeone, MD, discusses the benefit of using a gemcitabine “sandwich approach” in patients with resectable pancreatic cancer.

Diane M. Simeone, MD, explains which patients with pancreatic cancer should receive neoadjuvant therapy.

Diane M. Simeone, MD, discusses the impact of PARP inhibitors on pancreatic cancer.